Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Avrobio
Avrobio
Avrobio stops programs, halves head count and searches for exit
Fierce Biotech
Wed, 07/12/23 - 09:41 am
Avrobio
layoffs
gene therapy
Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf
Fierce Biotech
Mon, 05/22/23 - 11:35 am
Novartis
gene therapy
Avrobio
AVR-RD-04
With a new No. 1, Avrobio hopes to get investors back on gene therapy bandwagon
Fierce Biotech
Wed, 12/7/22 - 10:00 am
Avrobio
clinical trials
AVR-RD-02
Gaucher disease
Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program
Endpoints
Tue, 01/4/22 - 10:49 am
Fabry disease
clinical trials
Avrobio
Biotech Avrobio plans head-to-head Fabrazyme trial after FDA changes path to market
Fierce Biotech
Mon, 05/3/21 - 10:59 am
Avrobio
Fabry disease
gene therapy R&D
Sanofi
AVR-RD-01
Avrobio is using 'pods' to create gene therapies, and it believes the approach could change the game altogether
Endpoints
Fri, 04/16/21 - 12:01 am
Avrobio
gene therapy
drug manufacturing
A gene therapy pipeline takes shape for a cluster of rare diseases
BioPharma Dive
Mon, 02/15/21 - 11:43 pm
gene therapy
Fabry disease
Avrobio
Avrobio gene therapy eliminates toxic substrate in Fabry patient
Fierce Biotech
Mon, 02/8/21 - 10:26 am
Avrobio
gene therapy
Fabry disease
clinical trials
With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease
Stat
Wed, 02/6/19 - 09:40 am
Avrobio
Fabry disease
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
Xconomy
Thu, 06/21/18 - 12:04 pm
biotech
IPOs
Eidos Therapeutics
Avrobio
XERIS
Aptinyx
Kezar Life Sciences
Magenta Therapeutics
Rare Disease Biotechs Avrobio, Eidos Therapeutics File for IPOs
Xconomy
Sat, 05/26/18 - 09:22 am
Avrobio
Eidos Therapeutics
Rare Diseases
IPOs